Commercialisation of Biomarker Tests for Mental Illnesses: Advances and Obstacles

Trends in Biotechnology

Volumn 33, Issue 12, 2015, Pages 712-723

  Chan, Man K ^a   Cooper, Jason D ^a   Bahn, Sabine ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Blood based biomarker tests; Commercialisation; Mental illness

Indexed keywords

BIOMARKERS; BLOOD; CLINICAL RESEARCH; TESTING;

CLINICAL PRACTICES; COMMERCIALISATION; DATA VALIDITY; MENTAL ILLNESS; REPRODUCIBILITIES; RESEARCH FUNDING;

DISEASES;

ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN C3; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; EPIDERMAL GROWTH FACTOR; HYDROCORTISONE; MYELOPEROXIDASE; PROLACTIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANALYTICAL PARAMETERS; COMMERCIAL PHENOMENA; DIAGNOSTIC TEST APPROVAL; FOOD AND DRUG ADMINISTRATION; FRAUD; FUNDING; HUMAN; LABORATORY TEST; MENTAL DISEASE; MOLECULAR DIAGNOSIS; PERSONAL EXPERIENCE; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; STATISTICAL ANALYSIS; BLOOD; DIAGNOSTIC TEST; ECONOMICS; FINANCIAL MANAGEMENT; MEDICAL RESEARCH; MENTAL DISORDERS; ORGANIZATION AND MANAGEMENT; PREVENTIVE HEALTH SERVICE; PROCEDURES; SUPPLY AND DISTRIBUTION;

BIOMARKERS; BIOMEDICAL RESEARCH; CAPITAL FINANCING; DIAGNOSTIC SERVICES; DIAGNOSTIC TESTS, ROUTINE; MENTAL DISORDERS; REPRODUCIBILITY OF RESULTS;

EID: 84947922069     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2015.09.010     Document Type: Review

References (99)

1. Hewlett E., Moran V. Making Mental Health Count: The Social and Economic Costs of Neglecting Mental Health Care 2014, OECD Publishing.
2. World Health Organization Mental Health and Development: Targeting People with Mental Health Conditions as a Vulnerable Group 2010, WHO.
3. Olesen J., et al. The economic cost of brain disorders in Europe. Eur. J. Neurol. 2012, 19:155-162.
4. Wittchen H.U., et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 2011, 21:655-679.
5. Greer T.L., et al. Defining and measuring functional recovery from depression. CNS Drugs 2010, 24:267-284.
6. Stewart W.F., et al. Cost of lost productive work time among US workers with depression. JAMA 2003, 289:3135-3144.
7. OECD Sick on the Job? Myths and Realities about Mental Health and Work 2012, OECD Publishing.
8. Anon Mental Well-Being: For a Smart, Inclusive and Sustainable Europe 2011, European Union.
9. Rush A.J., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 2006, 163:1905-1917.
10. Mitchell A.J., et al. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 2009, 374:609-619.
11. Lora A., et al. Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle-income countries. Bull. World Health Organ. 2012, 90:47-54. 54A-54B.
12. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur. Arch. Psychiatry Clin. Neurosci. 2000, 250:274-285.
13. Chuma J., Mahadun P. Predicting the development of schizophrenia in high-risk populations: systematic review of the predictive validity of prodromal criteria. Br. J. Psychiatry 2011, 199:361-366.
14. Fusar-Poli P., et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch. Gen. Psychiatry 2012, 69:220-229.
15. Fusar-Poli P., et al. Attenuated psychosis syndrome: ready for DSM-5.1?. Annu. Rev. Clin. Psychol. 2014, 10:155-192.
16. van der Gaag M., et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr. Res. 2013, 149:56-62.
17. Anon The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines 1992, World Health Organization.
18. Follette W.C., Houts A.C. Models of scientific progress and the role of theory in taxonomy development: a case study of the DSM. J. Consult. Clin. Psychol. 1996, 64:1120-1132.
19. Yolken R.H., et al. Toxoplasma and schizophrenia. Parasite Immunol. 2009, 31:706-715.
20. Lovatt A., et al. Psychotic-like experiences, appraisals, and trauma. J. Nerv. Ment. Dis. 2010, 198:813-819.
21. Chan M.K., et al. Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. Prog. Neurobiol. 2014, 122:45-72.
22. Hepgul N., et al. Depression pathogenesis and treatment: what can we learn from blood mRNA expression?. BMC Med. 2013, 11:28.
23. Kalia M., Costa E.S.J. Biomarkers of psychiatric diseases: current status and future prospects. Metabolism 2015, 64:S11-S15.
24. Maes M., et al. Relationships between increased haptoglobin plasma levels and activation of cell-mediated immunity in depression. Biol. Psychiatry 1993, 34:690-701.
25. Maes M. A review on the acute phase response in major depression. Rev. Neurosci. 1993, 4:407-416.
26. Kaestner F., et al. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J. Affect. Disord. 2005, 87:305-311.
27. Penninx B.W., et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol. Psychiatry 2003, 54:566-572.
28. Maes M., et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997, 9:853-858.
29. Mikova O., et al. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur. Neuropsychopharmacol. 2001, 11:203-208.
30. Kim Y.K., et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol. Psychiatry 2002, 7:1107-1114.
31. Stelzhammer V., et al. Proteomic changes in serum of first onset, antidepressant drug-naive major depression patients. Int. J. Neuropsychopharmacol. 2014, 17:1599-1608.
32. Wong M.L., et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:325-330.
33. Cizza G., et al. Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression (POWER) study. J. Clin. Psychiatry 2010, 71:1079-1087.
34. Hryhorczuk C., et al. Metabolic disturbances connecting obesity and depression. Front. Neurosci. 2013, 7:177.
35. Mayes R., Horwitz A.V. DSM-III and the revolution in the classification of mental illness. J. Hist. Behav. Sci. 2005, 41:249-267.
36. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1987, APA. 3rd edn revised.
37. Morrison J.R. DSM-IV Made Easy: The Clinician's Guide to Diagnosis 1995, Guilford Press.
38. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, APA. 4th edn.
39. Fischer B.A. A review of American psychiatry through its diagnoses: the history and development of the Diagnostic and Statistical Manual of Mental Disorders. J. Nerv. Ment. Dis. 2012, 200:1022-1030.
40. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2013, APA. fifth edn.
41. Kupfer D.J., et al. DSM-5: the future arrived. JAMA 2013, 309:1691-1692.
42. Regier D.A., et al. DSM-5 field trials in the United States and Canada, Part II: test-retest reliability of selected categorical diagnoses. Am. J. Psychiatry 2013, 170:59-70.
43. Anon. (2013) DSM-5: by the book. The Economist May 18.
44. Ryan M.M., et al. Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. Mol. Psychiatry 2006, 11:965-978.
45. Swatton J.E., et al. Protein profiling of human postmortem brain using 2-dimensional fluorescence difference gel electrophoresis (2-D DIGE). Mol. Psychiatry 2004, 9:128-143.
46. Huang J.T., et al. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol. Psychiatry 2008, 13:1118-1128.
47. Chan M.K., et al. Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients. Mol. Psychiatry 2011, 16:1189-1202.
48. Tkachev D., et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362:798-805.
49. Lan M.J., et al. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol. Psychiatry 2009, 14:269-279.
50. Prabakaran S., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 2004, 9:684-697. 643.
51. Harris L.W., et al. Comparison of peripheral and central schizophrenia biomarker profiles. PLoS ONE 2012, 7:e46368.
52. Wang L., et al. Expression profiling of fibroblasts identifies cell cycle abnormalities in schizophrenia. J. Proteome Res. 2010, 9:521-527.
53. Schwarz E., et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 2010, 5:39-47.
54. Schwarz E., et al. Identification of a biological signature for schizophrenia in serum. Mol. Psychiatry 2012, 17:494-502.
55. Schwarz E., et al. Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways. Schizophr. Bull. 2013, 40:787-795.
56. Holmes E., et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 2006, 3:e327.
57. Herberth M., et al. Differential effects on T-cell function following exposure to serum from schizophrenia smokers. Mol. Psychiatry 2010, 15:364-371.
58. Huang J.T., et al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS ONE 2007, 2:e756.
59. Levin Y., et al. Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol. Psychiatry 2010, 15:1088-1100.
60. Chan M.K., et al. Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. Transl. Psychiatry 2015, 5:e601.
61. Papakostas G.I., et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol. Psychiatry 2013, 18:332-339.
62. Wong D.T., et al. The discovery of fluoxetine hydrochloride (Prozac). Nat. Rev. Drug Discov. 2005, 4:764-774.
63. Redei E.E., Mehta N.S. The promise of biomarkers in diagnosing major depression in primary care: the present and future. Curr. Psychiatry Rep. 2015, 17:601.
64. Amplion Market Trends for Biomarker-Based IVD Tests (2003-2014) Realizing the Promise of Precision Medicine 2015, Amplion.
65. Kobeissy F., et al. Biomarkers in psychiatry: how close are we?. Front. Psychiatry 2012, 3:114.
66. Pusztai L., et al. Reproducibility of research and preclinical validation: problems and solutions. Nat. Rev. Clin. Oncol. 2013, 10:720-724.
67. Anon. (2013) Unreliable research - trouble at the lab. The Economist Oct 19.
68. Gunn W. Reproducibility: fraud is not the big problem. Nature 2014, 505:483.
69. Bustin S.A. The reproducibility of biomedical research: sleepers awake!. Biomol. Detect. Quantif. 2014, 2:35-42.
70. Collins F.S., Tabak L.A. Policy: NIH plans to enhance reproducibility. Nature 2014, 505:612-613.
71. Steen R.G. Retractions in the scientific literature: is the incidence of research fraud increasing?. J. Med. Ethics 2011, 37:249-253.
72. Fanelli D. How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. PLoS ONE 2009, 4:e5738.
73. Ranstam J., et al. Fraud in medical research: an international survey of biostatisticians. ISCB Subcommittee on Fraud. Control. Clin. Trials 2000, 21:415-427.
74. Haenisch F., et al. Multiplex immunoassay analysis of plasma shows prominent upregulation of growth factor activity pathways linked to GSK3beta signaling in bipolar patients. J. Affect. Disord. 2014, 156:139-143.
75. Marton M.J., Weiner R. Practical guidance for implementing predictive biomarkers into early phase clinical studies. Biomed. Res. Int. 2013, 2013:891391.
76. Zheng W., He L. Multiplexed Immunoassays. Advances in Immunoassay Technology 2012, 144-164. InTech. H.L.C. Norman (Ed.).
77. Pavlou M.P., et al. The long journey of cancer biomarkers from the bench to the clinic. Clin. Chem. 2013, 59:147-157.
78. Houser B. Bio-Rad's Bio-Plex(R) suspension array system, xMAP technology overview. Arch. Physiol. Biochem. 2012, 118:192-196.
79. Fuzery A.K., et al. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin. Proteomics 2013, 10:13.
80. Leng S.X., et al. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J. Gerontol. A: Biol. Sci. Med. Sci. 2008, 63:879-884.
81. Ellington A.A., et al. Antibody-based protein multiplex platforms: technical and operational challenges. Clin. Chem. 2010, 56:186-193.
82. Cramer D.W., et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev. Res. (Phila.) 2011, 4:365-374.
83. Peduzzi P., et al. A simulation study of the number of events per variable in logistic regression analysis. J. Clin. Epidemiol. 1996, 49:1373-1379.
84. Huang J., et al. Adaptive Lasso for Sparse High-Dimensional Regression Models 2006, The University of Iowa.
85. James G., et al. An Introduction to Statistical Learning with Applications in R 2013, Springer-Verlag.
86. Zou H. The adaptive lasso and its oracle properties. J. Am. Stat. Assoc. 2006, 101:1418-1429.
87. State M.W., Geschwind D.H. Leveraging genetics and genomics to define the causes of mental illness. Biol. Psychiatry 2015, 77:3-5.
88. Gelernter J. Genetics of complex traits in psychiatry. Biol. Psychiatry 2015, 77:36-42.
89. Sokolowska I., et al. The potential of biomarkers in psychiatry: focus on proteomics. J. Neural Transm. 2015, 122(Suppl. 1):9-18.
90. Wood P.L. Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology. Neuropsychopharmacology 2014, 39:24-33.
91. Sauer S. Diagnostic proteomics: will this impact the clinic?. Proteomics Clin. Appl. 2013, 7:725-726.
92. Mischak H., et al. Implementation of proteomic biomarkers: making it work. Eur. J. Clin. Invest. 2012, 42:1027-1036.
93. Niculescu A.B., et al. Psychiatric blood biomarkers: avoiding jumping to premature negative or positive conclusions. Mol. Psychiatry 2015, 20:286-288.
94. Cyhlarove E., et al. Economic Burden of Mental Illness Cannot be Tackled without Research Investment 2010, Mental Health Foundation.
95. Green H., et al. Mental Health of Children and Young People in Great Britain 2004 2004, Palgrave.
96. Food and Drug Administration What does it mean for FDA to 'Classify' a Medical Device? 2015, FDA.
97. Food and Drug Administration What is the Difference between FDA-listed, 510(k) Exempt, Cleared and Approved Medical Devices? 2015, FDA.
98. American Society for Clinical Pathology (2010) Regulation of Laboratory Developed Tests, Policy Number 10-02. ASCP.
99. Weiss R.L. The long and winding regulatory road for laboratory-developed tests. Am. J. Clin. Pathol. 2012, 138:20-26.